Description du projet
Un système de chirurgie robotique avec retour tactile
De nombreuses procédures endovasculaires, telles que la chirurgie vasculaire périphérique et les interventions coronariennes, sont réalisées par la robotique, ce qui protège le personnel médical contre l’exposition aux rayons X nocifs. Le projet HAPGuide, financé par l’UE, a mis au point un système robotique innovant qui permet un retour tactile et le contrôle traditionnel des instruments endovasculaires. Les chirurgiens conservent leur niveau de perception, de visualisation et d’action, sans avoir besoin d’instruments spécialisés ou de cathéters coûteux. Le principal objectif du projet HAPGuide est de fournir cette technologie innovante à la pratique clinique pour que le monde entier puisse proposer des interventions endovasculaires plus sûres, plus rapides et plus efficaces, au bénéfice des patients, des médecins et des hôpitaux.
Objectif
"UAB ""Inovatyvi medicina"" has developed an innovative design of endovascular robotic system HAPGuide. This SMART and SENSING technology allows to perform endovascular procedures without medical personnel being exposed to harmful X-rays. HAPGuide solves the main issues of existing robotic systems and opens up possibilities for safer, faster and more effective endovascular interventions in EU and Worldwide. In comparison to existing systems (with only visual feedback and videogame like control) the main HAPGuide advantage is the haptic feedback and traditional control of endovascular instruments using fine-tuned surgeons’ perception-action-visualization abilities. Future developments involve HAPGuide use in telemedicine and partially automated functions via machine learning. Our system is designed to use all standard endovascular instruments and avoids the need of expensive catheters dedicated for the system. The primary target market of HAPGuide is cath labs performing percutaneous coronary interventions and peripheral vascular procedures in EU and US (more than 5.6 mln. procedures annually). The estimated market potential of HAPGuide robotic system in primary worldwide market exceeds €4 billion. The secondary target market would involve neurointerventional procedures while in the long-run expansion to telerobotics will create new market opportunities. Our revenue model involves four main components: 1) durable robotic HAPGuide system; 2) single use cassette; 3) annual service of the system; 4) HAPLearn training software. A multidisciplinary team with vast experience in medical sciences, medical device development, robotics, mechanical and electronic engineering, product design, commercialisation and business development has joined forces for the implementation of HAPGuide project aiming to bring the technology to clinical practice for benefit of patients, physicians and hospitals and exploit this €4 billion niche market commercial opportunity."
Champ scientifique
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesbasic medicineneurologystroke
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringrobotics
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
- natural sciencescomputer and information sciencessoftwaresoftware applicationsvideo games
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
44353 KAUNAS
Lituanie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.